Full-Time
Medical Science Liaison
Ohio Valley
Updated on 9/9/2026
SK Life Science
Develops CNS and cancer therapies
Compensation Overview
$160k - $215k/yr
United States
Remote
Field-based territory covers Kentucky, Ohio, western Pennsylvania, and West Virginia; travel is 50% or more, including domestic and international travel as needed.
PharmD, PhD, MD
 Biology & Biotech |
|---|
Get referred to SK Life Science
See people who can refer or advise you
- The candidate must hold an MD, Doctor of Pharmacy, Nurse Practitioner, or PhD degree and have appropriate clinical or scientific experience.
- The candidate should have knowledge and experience in medical neurosciences, including epilepsy or other neurological disorders.
- The candidate should have a clear understanding of regional medical practice and clinical decision-making regarding patient care.
- The candidate must be able to identify unmet medical, educational, and research needs within the regional medical community.
- The candidate must be able to interpret key scientific data and translate it to meet educational and research needs.
- The candidate must be able to address educational and research needs through delivery of current scientific and evidence-based data.
- The candidate must understand healthcare systems affecting patient care.
- The candidate must understand the design and execution of research studies.
- The candidate must demonstrate communication and presentation skills.
- The candidate must be able to think strategically.
- The candidate must be willing and able to travel 50% or more, including domestic and international travel as needed.
- Provide non-promotional scientific, educational, and research support for the company’s central nervous system portfolio.
- Develop and maintain relationships with key central nervous system experts and build an informed advocacy base for the central nervous system franchise.
- Provide accurate and updated clinical, scientific, and medical information to key opinion leaders, healthcare professionals, treatment decision-makers, payers, providers, and other members of the scientific and healthcare communities in compliance with company policies.
- Maintain business and clinical knowledge of the epilepsy treatment landscape, including treatment strategies, competitors, and new therapeutic developments.
- Increase the company’s visibility among leaders in epilepsy and central nervous system/neurology.
- Establish and maintain collaborative relationships with epilepsy and neurology experts, investigators, and institutions relevant to product development.
- Participate in medical education for healthcare professionals through office-visit presentations, investigator meetings, advisory boards, medical meetings, and other appropriate venues.
- Collaborate with the clinical team and clinical research associates to coordinate and optimize educational and research support for clinical-trial sites and investigators.
- Respond to unsolicited requests regarding investigator-sponsored studies and support submissions through appropriate internal processes.
- Respond to unsolicited requests for medical information about supported products and disease-state areas.
- Deliver effective clinical presentations to internal and external audiences and tailor them to audience needs.
- Identify and communicate clinical and research issues and insights from industry leaders to appropriate departments to inform research, development, and product strategies.
- Facilitate identification of medical-community educational needs concerning epilepsy management and appropriate or inappropriate use of company products.
- Collaborate with internal and external stakeholders to support key opinion leader needs.
- Maintain clinical expertise through continuing education, relevant symposiums, scientific workshops, key-journal review, internal training, presentations, and journal clubs.
- Communicate appropriately with Medical, Regulatory, and Legal personnel to ensure required timelines and procedures are met.
- Follow regulatory and compliance guidelines and company policies when disseminating scientific information and responding to unsolicited medical-information requests.
- Enhance the clinical and scientific knowledge of customers and colleagues through education and appropriate scientific exchange.
- Identify local and regional educational gaps and needs and apply field medical support aligned with medical strategy.
- Provide field updates on topics of interest.
- Address administrative and reporting needs promptly or as requested by management.
- Industry or clinical experience in epilepsy and/or central nervous system/neurology.
- Previous pharmaceutical industry experience.
SK Life Science is a U.S. subsidiary focused on developing medicines for central nervous system (CNS) disorders and cancer. Its work centers on researching and bringing pharmaceutical treatments to market that address neurological diseases and oncology, leveraging the broader SK Group’s resources and expertise. The company’s products work by targeting disease mechanisms in CNS conditions or cancer, delivered through conventional pharmaceutical formulations developed through its science-driven pipeline (as part of SK Biopharmaceuticals). What sets SK Life Science apart from competitors is its backing by SK Group and SK Biopharmaceuticals, enabling strong research, development, and global scale, as well as a stated commitment to real patient impact in CNS and oncology. The company aims to transform lives by delivering meaningful treatments that improve outcomes for patients with CNS disorders and cancer.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
Paramus, New Jersey
Founded
N/A
Get referred to SK Life Science
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 5, 2026 U.S. XCOPRI sales reached 224.4 billion won, up 45.6% year-over-year.
- April 16, 2026 Epilepsy Connect expands KOL influence with APPs and Medscape education.
- Q1 2026 revenue hit 227.9 billion won, while operating profit reached 89.8 billion won.
What critics are saying
- August 19, 2026 MSN settlement opened a future generic pathway for XCOPRI.
- XCOPRI drove 98.5% of SK Biopharmaceuticals sales in first-half 2026, creating existential concentration risk.
- If cenobamate patent fences fail, 2032 generic erosion crushes SK Life Science’s employer value.
What makes SK Life Science unique
- SK Biopharmaceuticals independently developed XCOPRI, Korea’s only homegrown U.S.-commercialized antiseizure drug.
- XCOPRI’s dual mechanism strengthens cenobamate’s differentiation in refractory focal-seizure treatment.
- March 2026 ownership simplification made SK Life Science Labs and SK Life Science fully controlled.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Company News
SK Biopharmaceuticals licenses Biohaven epilepsy drug opakalim. Healthcare Supply Chain August 30, 2026 Highlights. * SK Biopharmaceuticals is expanding its U.S. strategy with a deal for the late-stage epilepsy drug opakalim from Biohaven. * SK will pay $400 million up front for global rights to opakalim, with additional milestone payments and royalties possible. * The drug is in Phase 3 testing for focal onset epilepsy, and SK plans a U.S. launch in 2029 if it wins FDA approval. SK Biopharmaceuticals, a South Korea-based drugmaker that already sells an FDA-approved epilepsy medicine, is expanding its U.S. strategy through a deal for opakalim, a late-stage molecule from Biohaven. The drug uses a different mechanism of action for seizure disorder treatment. According to the terms announced Aug. 26, SK will pay $400 million up front for global rights to the Biohaven drug. The payment includes $350 million at deal closing and $50 million one year later. SK could pay Biohaven up to $395 million more tied to milestones, along with royalties from sales of an approved product. A portion of those payments will go to Knopp Biosciences, which originally developed opakalim and formed Channel Bio. Biohaven has advanced opakalim to Phase 3 testing in focal onset epilepsy. Preliminary Phase 2/3 data are expected by the end of this year, and a second readout is expected in 2028. If the drug passes FDA review, SK said it plans to launch opakalim in the U.S. in 2029 through SK Life Science, its New Jersey-based subsidiary. Biohaven added opakalim to its pipeline through the $100 million purchase of Channel Bio in 2022. Analysts said the deal gives Biohaven non-dilutive capital and allows it to focus on other pipeline programs, including taldefgrobep alfa, BHV-1300, and BHV-1400. The company reported cash of about $270.5 million as of June 30. company spotlight Osirium. In the current world of outsourcing, it can be hard to see who has privileged access to what on your systems. These days, the lowest paid people have the highest privileges - and they may not even work for your organisation. Osirium readdresses this balance for end-user organisations and uniquely allows MSSPs to manage tens of thousands of account credentials, outsource safely and keep their clients happy on the compliance front. more top stories August 31, 2026 * Health tech companies announced several major funding rounds in August. * Cityblock raised $116 million in Series E funding to support its acquisition of Homeward Health and invest in its combined platform. * Happy Health, Flagler Health, and Network Bio also reported funding rounds of $75 million, $50 million, and $50 million, respectively. Health tech companies made several major funding announcements in August, and the roundup highlighted some of the biggest funding rounds of the month. The list was presented as a selection of notable transactions and was not intended to be comprehensive. Cityblock raised $116 million in Series E funding. The New York City-based company offers clinical care, behavioral health care, and social care in patients' homes, virtually, and in community-based clinics. It primarily serves Medicaid and dual-eligible populations. The company's AI-powered operating system aggregates physical, behavioral, and social health data to provide care teams with predictive insights into members. The $116 million round supported Cityblock's acquisition of Homeward Health, a rural healthcare provider. The funding will be used to invest in the combined platform, including optimizing operations, the care model, technology, and data infrastructure. Happy Health secured $75 million in funding from ARCH Venture Partners and OpenLoop. Flagler Health raised $50 million in Series B funding led by Bessemer Venture Partners, and Network Bio launched with $50 million in funding from Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, and JSL Health Capital. August 31, 2026 * August brought a series of executive hires, exits, and layoffs across healthcare organizations. * New appointments included leaders at Adonis, Cone Health, Humana, Mayo Clinic, Merck, Providence, and Quantum Health. * Layoffs were announced by Cellares, MaineHealth, and Sharp HealthCare, while Centene and Tufts Medicine reported leadership exits. This monthly roundup highlights selected hiring news in healthcare and is not intended to be comprehensive. It includes executive appointments, resignations, promotions, and layoffs shared during the month. The roundup invites organizations to share news about an executive appointment, resignation, or layoff for future inclusion. Among the hires and promotions, Adonis named Alison Bloom-Kiefer as chief product officer and promoted Doug Pickett to chief revenue officer. Cone Health appointed Ryan Christensen as chief value-based care officer, while Humana selected J.P Holland as its new Medicaid president. Mayo Clinic named Arun Kumar Bhaskara-Baba as its new CIO, and Merck brought in Bart Gourley as chief AI officer. Providence named Kevin Smith as its new CFO, with a planned start in October after he leaves SSM Health. Quantum Health hired Jamie Hall as chief commercial officer and Daniel Stein as chief strategy officer. The roundup also noted that Bloom-Kiefer joined Adonis from Oscar Health, Pickett came from Cedar, Holland joined from Johns Hopkins Health Plans, and Bhaskara-Baba arrived from Honeywell Aerospace and Defense. On the exits side, Centene CFO Drew Asher said he will retire at the end of the year after serving since 2021. Tufts Medicine CEO Mike Dandorph and CFO Andrew Devoe also announced they are stepping down as the health system begins a major financial turnaround effort. In layoffs, Cellares said it plans to cut about 100 employees after Bristol Myers Squibb ended its manufacturing partnership, while MaineHealth is cutting 83 positions and Sharp HealthCare said 260 employees are affected by an organizational realignment.
Vacancy rate rises in Life Science sector of Northern NJ. Vacancy rates for the life sciences category in Northern New Jersey rose in the second quarter, according to Savills's recently released Q2 2026 Life Sciences Market Reports. Overall vacancy increased to 24.4%, up 890 basis points year over year from 15.5%, primarily because of the addition of several large availabilities to the market. Sublease vacancy also rose sharply, increasing to 3% in the second quarter from 1.6% in the same period of 2025. Advance Realty Investors unveiled plans for Continuum, a 1.1-million-square-foot life sciences and advanced manufacturing campus in Bridgewater and broke ground on the first phase, which will include up to 830,000 square feet of purpose-built life sciences space. SK Biopharmaceuticals launched SK Life Science LinX, a new innovation facility in Paramus that will provide collaborative workspace and commercialization support for South Korean biotech and pharmaceutical companies entering the U.S. Among the more notable leases in the quarter were: Medline Industries for 195,416 square feet in Carteret in the Middlesex submarket; Sandoz for 78,391 square feet in Plainsboro in the Princeton submarket; Organon for 70,000 square feet in Florham Park in the Morris submarket; Regenity Biosciences for 60,215 square feet in Oakland in the West Bergen submarket; and Capintec for 25,565 square feet in Florham Park in the Morris submarket.
SK Life Science has launched Epilepsy Connect, a free digital platform designed to support advanced practice providers in epilepsy care across the United States. The platform offers educational resources, accredited CME/CE webinars provided by Medscape, and peer networking tools. The initiative addresses a gap identified in the company's Hope, Hesitancy, and Hard Truths survey, which found that whilst 65% of epileptologists regularly discuss alternative treatment options, only 44% of APPs do the same. Meanwhile, 90% of patients expressed interest in discussing treatment changes. Epilepsy Connect provides on-demand courses covering clinical foundations, treatment approaches and patient communication strategies. The platform serves the 3.4 million people living with epilepsy in the US by strengthening APP capabilities in patient care.
SK Life Science, Inc. launches Epilepsy Connect to empower advanced practice providers in Epilepsy care. PR Newswire Today at 5:04am PDT Key Facts: * SK Life Science, Inc. has launched Epilepsy Connect, a new digital platform designed to empower advanced practice providers (APPs) in epilepsy care. * Epilepsy Connect provides complimentary, U.S.-only access to educational resources, accredited CME/CE webinars, provided by Medscape, and peer networking tools for APPs. * The platform includes on-demand epilepsy courses, covering clinical foundations, treatment approaches, and patient communication strategies. * APP Connect enables peer-to-peer networking, allowing advanced practice providers to connect, share insights, and learn from one another nationwide. * The launch supports the 3.4 million people living with epilepsy in the United States by strengthening the role of APPs in patient care. * Insights from SK Life Science, Inc.'s Hope, Hesitancy, and Hard Truths survey highlight an opportunity to expand treatment discussions, with fewer APPs reporting routine conversations about alternative treatment options compared to epileptologists. * 90% of patients report interest in discussing treatment changes, underscoring the need for accessible educational resources for APPs. * Additional survey methodology details will be presented at the upcoming American Academy of Neurology Annual Meeting. PARAMUS, N.J., April 16, 2026 /PRNewswire/ - SK Life Science, Inc., a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., today announced the launch of Epilepsy Connect, a new digital platform designed to empower advanced practice providers (APPs) with educational resources, accredited learning opportunities, and peer networking tools aimed at enhancing care for people living with epilepsy. Epilepsy Connect is a centralized epilepsy education platform tailored specifically to the needs of advanced practice providers (APPs), who play an increasingly vital role in the management of epilepsy across the United States. With approximately 3.4 million people living with epilepsy nationwide, expanding access to epilepsy education, clinical resources, and peer networking for APPs is critical to supporting informed, patient-centered epilepsy care. "Advanced practice providers are an essential part of the epilepsy care team, and their role continues to grow as they help meet the needs of patients across diverse care settings," said Lisa Finnerty Lester, Vice President of Commercial Excellence at SK Life Science, Inc. "With Epilepsy Connect, we are proud to support and empower APPs by providing epilepsy-specific educational resources and professional development tools designed for their needs, helping them to continue to build on their knowledge of epilepsy, strengthen patient conversations, and ultimately enhance care for people living with epilepsy." Enrollment in Epilepsy Connect is complimentary and provides APPs with full access to a range of epilepsy education and professional development resources, including: * Epilepsy Courses: Focused learning modules that strengthen key aspects of epilepsy care, including clinical foundations such as neuroanatomy and seizure classification, epilepsy treatment options and mechanisms of action (MoA), and communication strategies that support shared decision-making with patients and caregivers. * Accredited Webinars: Live and on-demand continuing medical education (CME/CE) for epilepsy care, provided by Medscape, designed to provide flexible, high-quality learning that fits into APPs' clinical schedules. * APP Connect: An optional feature that enables APPs to connect and collaborate with peers across the country, fostering peer-to-peer learning and knowledge exchange among advanced practice providers in epilepsy care. The launch of Epilepsy Connect builds on SKLSI's broader commitment to advancing epilepsy awareness, education, and healthcare professional support in the United States, while strengthening the growing community of APPs as key care providers. It also reflects insights from the company's Hope, Hesitancy, and Hard Truths survey, which identified opportunities to further support clinical conversations about epilepsy treatment options. While 65% of epileptologists report regularly discussing alternative treatment options as part of routine care, 44% of APPs and 35% of neurologists report doing the same. At the same time, 90% of patients expressed interest in discussing options related to switching or adding medications to their treatment regimen. These findings reinforce the opportunity to further equip APPs with accessible, practical epilepsy education resources that support informed, confident discussions with patients. Epilepsy Connect is designed to help address this need - empowering APPs with the knowledge and tools to deliver comprehensive, patient-centered epilepsy care. Additional details on the Hope, Hesitancy, and Hard Truths survey methodology will be presented at the upcoming American Academy of Neurology Annual Meeting. Epilepsy Connect is intended for U.S. advanced practice providers (APPs) only and is designed to support ongoing continuing education in epilepsy care. About Epilepsy Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures and is the fourth most common neurological condition. * Approximately 3.4 million people in the United States are living with epilepsy * Approximately 150,000 new cases are diagnosed each year in the U.S. * Nearly 40% of people with epilepsy do not achieve seizure freedom despite available treatments According to the Centers for Disease Control and Prevention and the Epilepsy Foundation, epilepsy can impact safety, daily functioning, and overall quality of life. What is Epilepsy Connect? Epilepsy Connect is an epilepsy education platform offered at no cost to U.S. advanced practice providers (APPs), designed to support ongoing learning, professional development, and peer networking in epilepsy care. What resources are available on Epilepsy Connect? Epilepsy Connect provides access to a range of epilepsy education resources for APPs, including: * On-demand epilepsy courses covering clinical foundations, treatment approaches, and patient communication * Live and on-demand continuing medical education (CME/CE) webinars, provided by Medscape * APP Connect, a peer networking feature for networking and knowledge exchange Is Epilepsy Connect free to use? Yes. Enrollment is complimentary, and registered users receive full access to all available courses, webinars, and platform features. What is APP Connect? APP Connect is an optional feature within Epilepsy Connect that enables advanced practice providers to connect with peers, share insights, and collaborate with other APPs involved in epilepsy care across the United States. Why did SK Life Science, Inc. create Epilepsy Connect? Epilepsy Connect was developed as part of SK Life Science, Inc.'s commitment to advancing epilepsy awareness, education, and support for advanced practice providers. Insights from the company's Hope, Hesitancy, and Hard Truths survey highlighted an opportunity to expand access to educational resources that support clinical conversations and informed decision-making in epilepsy care. About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd. SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with 12 compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content screening, computer-aided drug design, combinatorial chemistry, and integrating artificial intelligence across discovery, development, and operations to accelerate innovation, the companies drive R&D efforts in biology/discovery, medicinal chemistry, pharmacology, and clinical development. For more information, visit www.sklifescienceinc.com. SOURCE SK Life Science, Inc. This is a paid placement. For further inquiries, please contact PR Newswire directly.
PARAMUS, N.J., April 4, 2025 /PRNewswire/ -- SK Life Science, Inc., a global leader in developing treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., will present meaningful encore data on XCOPRI® (cenobamate tablets) CV, an anti-seizure medication, at the 77th American Academy of Neurology (AAN) Annual Meeting, taking place April 5-9, 2025, in San Diego, California. This presentation reinforces the growing body of clinical and real-world evidence supporting cenobamate's role in reducing seizure activity and optimizing epilepsy management."Our goal at SK Life Science is to redefine seizure management by advancing research and education that translates into meaningful improvements for people living with epilepsy," said Louis Ferrari, BS, RPh, MBA, vice president, Medical Affairs at SK Life Science, Inc. "Seizure freedom remains an elusive, yet critical, objective for many patients, and this research offers valuable insights into how RNS data can be used as an objective measure to assess the efficacy of XCOPRI, and possibly other add-on anti-seizure medications."At AAN 2025, SK Life Science will highlight the impact of cenobamate on RNS epileptiform events. A retrospective, multicenter, observational, 24-week study among 37 patients with uncontrolled seizures showed a meaningful reduction in epileptiform events and clinically reported seizures during adjunctive cenobamate treatment. Results from this analysis support, through electrocorticographic data and observation of clinical seizures, the effectiveness of cenobamate in the treatment of focal seizures.Additional clinical and real-world data exploring cenobamate's efficacy, safety, and therapeutic potential in diverse patient populations will also be presented. Select SK Life Science posters presented at 2025 AAN include:Title: The Effect of Cenobamate on Responsive Neurostimulation Epileptiform Events (Aboumatar et al)Session: P5: Epilepsy/Clinical Neurophysiology (EEG): Neuromodulation Devices and Seizure TrackingDate/Time: Monday, April 7, from 8:00 a.m